News

Stryker Bets Big on Blood Clots with $4.9 Billion Inari Medical Acquisition

• By John K. Waters
• 01/06/2025

Medical device giant Stryker has unveiled plans to acquire Irvine, California-based Inari Medical in an all-cash deal valued at $4.9 billion. The move positions Stryker as a major force in the treatment of venous thromboembolism (VTE) and other vascular diseases, adding momentum to its growing endovascular portfolio.

Under the deal’s terms, Stryker will pay $80 per share for Inari, a premium that sent the target company’s stock soaring by over 30% during regular trading and an additional 21% after hours. The acquisition—expected to close by Q1 2025—marks a strategic expansion into a sector where innovation and demand are on the rise.

"The acquisition of Inari broadens Stryker’s ability to deliver life-saving treatments for patients battling vascular diseases," Stryker CEO Kevin Lobo told Reuters. "This complements our mission to elevate care standards in venous thromboembolism and endovascular procedures."

Inari specializes in developing cutting-edge devices to treat blood clots, including pulmonary embolism and deep vein thrombosis. Founded in 2013, the company has seen surging demand for its solutions as deferred procedures from the pandemic era begin to rebound. In its most recent quarter, Inari posted a 21% revenue growth despite an operating loss of $13.6 million. The company forecasts breaking even by year’s end, riding strong demand for its tech-forward solutions.

For Stryker, the acquisition is a natural fit. The Michigan-based company, already a titan in orthopedics, neurotechnology, and spinal devices, has a market value of $138 billion and raised its annual profit forecast after robust growth in surgical and medical device demand.

The timing couldn’t be better. The pandemic-driven surge in elective procedures is reshaping the medical device landscape, and Inari’s expertise in tackling blood clots comes as vascular health becomes a growing priority for aging populations.

Inari’s journey to the deal involved exploring acquisition interest from multiple suitors, but Stryker’s offer won out, with both boards approving the transaction.

This blockbuster buy marks more than just a business expansion—it’s Stryker doubling down on innovation at the intersection of vascular care and cutting-edge medical technology. As patients demand faster, safer, and more effective solutions, Stryker and Inari are poised to lead the charge.